JP2006508958A5 - - Google Patents

Download PDF

Info

Publication number
JP2006508958A5
JP2006508958A5 JP2004551161A JP2004551161A JP2006508958A5 JP 2006508958 A5 JP2006508958 A5 JP 2006508958A5 JP 2004551161 A JP2004551161 A JP 2004551161A JP 2004551161 A JP2004551161 A JP 2004551161A JP 2006508958 A5 JP2006508958 A5 JP 2006508958A5
Authority
JP
Japan
Prior art keywords
acid
composition according
pharmaceutical composition
anticancer agent
carnitine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004551161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508958A (ja
Filing date
Publication date
Priority claimed from US10/292,823 external-priority patent/US20030199535A1/en
Application filed filed Critical
Publication of JP2006508958A publication Critical patent/JP2006508958A/ja
Publication of JP2006508958A5 publication Critical patent/JP2006508958A5/ja
Pending legal-status Critical Current

Links

JP2004551161A 2002-11-13 2003-10-23 抗癌剤により誘発される末梢神経障害を予防および/または処置するための医薬品 Pending JP2006508958A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/292,823 US20030199535A1 (en) 1998-07-30 2002-11-13 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
PCT/IT2003/000656 WO2004043454A1 (en) 2002-11-13 2003-10-23 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents

Publications (2)

Publication Number Publication Date
JP2006508958A JP2006508958A (ja) 2006-03-16
JP2006508958A5 true JP2006508958A5 (enExample) 2006-11-30

Family

ID=32312146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004551161A Pending JP2006508958A (ja) 2002-11-13 2003-10-23 抗癌剤により誘発される末梢神経障害を予防および/または処置するための医薬品

Country Status (19)

Country Link
US (2) US20030199535A1 (enExample)
EP (1) EP1562577B1 (enExample)
JP (1) JP2006508958A (enExample)
KR (1) KR20050075012A (enExample)
CN (1) CN1708297A (enExample)
AR (1) AR041947A1 (enExample)
AT (1) ATE526958T1 (enExample)
AU (2) AU2003283807B2 (enExample)
BR (1) BR0316131A (enExample)
CA (1) CA2505937C (enExample)
CY (1) CY1112399T1 (enExample)
DK (1) DK1562577T3 (enExample)
ES (1) ES2374503T3 (enExample)
MX (1) MXPA05004752A (enExample)
PL (1) PL379244A1 (enExample)
PT (1) PT1562577E (enExample)
SI (1) SI1562577T1 (enExample)
TW (1) TWI362260B (enExample)
WO (1) WO2004043454A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018767A2 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
JP4208036B1 (ja) * 2007-04-26 2009-01-14 日本新薬株式会社 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物
WO2009028605A1 (ja) * 2007-08-31 2009-03-05 Kyushu University, National University Corporation 抗がん剤による末梢神経障害の予防又は軽減剤
AU2008348717B2 (en) * 2007-10-30 2013-09-19 Trophos Novel composition for treating the side effects of anticancer treatments
EA201170732A1 (ru) * 2008-12-01 2011-12-30 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
ITPZ20130005A1 (it) * 2013-07-05 2015-01-06 Teodosio Antonio Ferrara Metabolismo energetico e omeostasi
CN110121563A (zh) 2016-11-09 2019-08-13 奇根科学有限责任公司 在边合成边测序中作为成像试剂的光保护混合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713370A (en) * 1972-11-06 1987-12-15 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
US4599352A (en) * 1984-03-01 1986-07-08 The United States Of America As Represented By The Department Of Health And Human Services Antineoplastic platinum (IV) complexes and compositions
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung

Similar Documents

Publication Publication Date Title
JP2002521428A5 (enExample)
ES2431570T3 (es) Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención
JP2024507938A5 (enExample)
JP2006523216A5 (enExample)
JP2004519493A5 (enExample)
JP2005500357A5 (enExample)
JP2001520189A5 (enExample)
JP2020523354A5 (enExample)
JP2024516795A5 (enExample)
CA2505937A1 (en) Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents
JP2008514577A5 (enExample)
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
CN102215838B (zh) 烷酰基l-肉毒碱联合化学治疗药在治疗赘生物中的应用
ME02364B (me) Jedinjenja za supresiju poremećaja perifernih nerava indukovanih anti-kancerogenim sredstvom
JP2019513812A5 (enExample)
US20260092079A1 (en) Manufacture method for aqueous formulation of manganese-containing coordination complex, formulation, and method of treatment
EP1206256B1 (en) Combination therapy using pentafluorobenzenesulfonamide and platin compound
JP2017526719A5 (enExample)
ES2536534T3 (es) Agente terapéutico o agente profiláctico para el dolor neuropático
JP2020520385A5 (enExample)
RU2010121882A (ru) Новая композиция для лечения побочных эффектов противораковой терапии
AU2007321218A1 (en) Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
JP2006505499A5 (enExample)
CN1553803A (zh) 4-吡啶基甲基酞嗪在治疗癌症中的应用
RU2013108223A (ru) Лечение когнитивных нарушений определенными агонистами рецептора никотиновой кислоты альфа-7 в сочетании с ингибиторами ацетилхолинэстеразы